Invivyd (IVVD) Long-Term Deferred Tax (2023 - 2025)
Invivyd (IVVD) reported Long-Term Deferred Tax of $719000.0 for Q4 2025, down 99.64% quarter-over-quarter from $201.1 million in Q4 2023.
Invivyd (IVVD) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Invivyd has reported Long-Term Deferred Tax for 2 years, with the latest figure at $719000.0 in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $719000.0; the trailing twelve-month figure through Dec 2025 stood at $719000.0 (changed N/A YoY), and the FY2025 full-year result was $719000.0, changed N/A from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $719000.0, down from $201.1 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $201.1 million in Q4 2023, with the low at $719000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Invivyd | 130.80 Mn | -95.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 719,000.00 |
| Dec 31, 2023 | 201.08 Mn |